Clinical Trials on Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Total 4965 results

Mian XI

Completed

Identification of Breath Biomarkers in Esophageal Cancer (EC-CRT-005)

Esophageal Squamous Cell Carcinoma

China
Sunshine Lake Pharma Co., Ltd.

Completed

Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

Esophageal Squamous Cell Carcinoma

China
Peking University
Peking University Cancer Hospital & Institute

Suspended

Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Shanghai Cancer Hospital, China

Completed

Precisely Estimation of the Prognostic Value of Lymph Node in ESCC

Esophageal Squamous Cell Carcinoma
Novartis Pharmaceuticals

Completed

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

Taiwan, Spain, Canada, Singapore, Hong Kong, Korea, Republic of, Belgium, United Kingdom, United States
Samsung Medical Center
Ono Pharmaceutical Co. Ltd

Unknown

Neoadjuvant Nivolumab for Operable Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Samsung Medical Center

Unknown

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

Korea, Republic of
National Cancer Institute (NCI)

Terminated

NCI UNC Project ESCC

Esophageal Squamous Cell Carcinoma

Malawi
Sun Yat-sen University

Completed

Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital

Unknown

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Shandong University

Unknown

Whether it is More Appropriate to Spray Lugol's Solution From Cervical Esophagus to Esophagogastric Junction

Esophageal Squamous Cell Carcinoma
Tiago Biachi

Unknown

Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma (DESC)

Esophageal Squamous Cell Carcinoma

Brazil
Sinocelltech Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Unknown

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
Fudan University

Unknown

Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Asan Medical Center

Terminated

Role of Esophagectomy in Complete Responders to CCRT (ESOPRESSO)

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Mianyang Central Hospital

Unknown

S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital
Tongji Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University... and other collaborators

Unknown

Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms

China
Fudan University

Recruiting

TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
West China Hospital

Recruiting

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Recruiting

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Tao Jiang

Not yet recruiting

Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Xinxiang Medical...
BeiGene

Not yet recruiting

Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

ESCC
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC

Esophageal Squamous Cell Carcinoma

China
Jiangxi Provincial Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients (ALTER-E005)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Carcinoma, Squamous Cell | Esophageal Neoplasms | Esophageal Diseases | Neoplasms, Squamous Cell | Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital
Bristol-Myers Squibb

Recruiting

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (ETNT)

Esophageal Squamous Cell Carcinoma

China
Fujian Cancer Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (REVO)

Esophageal Neoplasms | Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...
Shanxi Province Cancer Hospital; Cancer Institute and Hospital, Chinese Academy... and other collaborators

Recruiting

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) (KEYSTONE-002)

Esophageal Squamous Cell Carcinoma

China
Wei Ren

Recruiting

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Hebei Medical University Fourth Hospital

Recruiting

Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma (NTNC)

Esophageal Squamous Cell Carcinoma

China
Hebei Medical University Fourth Hospital

Not yet recruiting

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Wangluowei

Active, not recruiting

Changhai Multimodal Esophageal Cancer Cohort (CMECC)

Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital

Completed

Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma

Time

China
Yonsei University

Completed

Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Qiu Guoqin

Enrolling by invitation

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma (CRIS)

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Completed

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Huai'an First People's Hospital
The Second People's Hospital of Huai'an; lian shui county People's Hospital; xuyi... and other collaborators

Completed

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Completed

Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma (ESO-Shanghai9)

Esophageal Squamous Cell Carcinoma

China
Hecheng Li M.D., Ph.D

Completed

Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus (PALACE-1)

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Enrolling by invitation

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
First Affiliated Hospital Xi'an Jiaotong University

Active, not recruiting

Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES) (TINES)

Esophageal Squamous Cell Carcinoma

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University

Completed

Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Withdrawn

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Esophageal Squamous Cell Carcinoma
Sun Yat-sen University

Completed

Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China

3

Subscribe